Recent Updates
Recently added Catalysts
CGEM Positive Sentiment

Zipalertinib Plus Chemotherapy First-Line Phase 3 REZILIENT3 Trial Data Selected for Presidential Symposium Presentation at the IASLC 2026 World Conference on Lung Cancer

Wednesday, August 19, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The Phase 3 REZILIENT3 trial results for Zipalertinib combined with chemotherapy have been selected for presentation at the IASLC 2026 World Conference on Lung Cancer. The interim analysis indicates that the trial successfully met its primary endpoint of progression-free survival in patients with EGFR exon 20 insertion mutation non-small cell lung cancer (NSCLC).

Market Sentiment Analysis

POSITIVE FACTORS

  • The trial met its primary endpoint of progression-free survival.
  • Results will be presented at a prestigious symposium.
  • The treatment targets a specific mutation in NSCLC.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+93%
120-day peak, hindsight
Typical move
6.7%
average across 8 past catalysts
Cash runway
~17 mo
Low dilution risk
Lead asset
CLN-619
Phase 1 · Multiple Myeloma

Full Press Release Details

Presentation will feature results from the planned interim analysis of the Phase 3 REZILIENT3 trial, which met its primary endpoint of progression-free survival in first line EGFR exon 20 insertion mutation NSCLC PRINCETON, N.J., CAMBRIDGE, Mass., August 19, 2026 — Taiho Oncology, Inc.

Frequently Asked Questions

What is the REZILIENT3 trial about?

The REZILIENT3 trial studies Zipalertinib combined with chemotherapy for NSCLC.

What was the primary endpoint of the trial?

The trial met its primary endpoint of progression-free survival.

Where will the trial results be presented?

Results will be presented at the IASLC 2026 World Conference on Lung Cancer.

What mutation does Zipalertinib target?

Zipalertinib targets EGFR exon 20 insertion mutations in NSCLC.

ShareAdd on Google
Tags: CGEM Viatris Investor Conferences Healthcare Zipalertinib Phase 3 trial NSCLC EGFR mutation Taiho Oncology
Last updated: Aug 19, 2026

Biotech snapshot

Cash runway
$335M liquidity · $19M/mo burn
~17 mo
Low dilution risk
Lead asset
CLN-619Phase 1
Multiple Myeloma →

Catalyst track record

+93%
best trade around CGEM's most recent catalyst

Peak hindsight return over a 120-day window, across 8 tracked FDA/PDUFA catalysts for CGEM.

See every catalyst's timing & PoA →